Yayın:
Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorCatherine Thiéblemont
dc.contributor.authorВ Я Мельниченко
dc.contributor.authorKrimo Bouabdallah
dc.contributor.authorJan Waleswski
dc.contributor.authorAlejandro Majlis
dc.contributor.authorLaura Maria Fogliatto
dc.contributor.authorAlejandro Martı́n
dc.contributor.authorBeth Christian
dc.contributor.authorZafer Gülbaş
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorGuilherme Fleury Perini
dc.contributor.authorGilles Salles
dc.contributor.authorMargaret A. Shipp
dc.contributor.authorSeth Thompson
dc.contributor.authorSamhita Chakraborty
dc.contributor.authorPatricia Marinello
dc.contributor.authorPhilippe Armand
dc.contributor.orcid0000-0002-2112-2651
dc.contributor.orcid0000-0002-9941-2448
dc.contributor.orcid0000-0002-6728-6264
dc.contributor.orcid0000-0002-4425-7823
dc.contributor.orcid0000-0002-0610-7971
dc.contributor.orcid0000-0001-6330-1028
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0001-7235-1334
dc.contributor.orcid0000-0002-9541-8666
dc.contributor.orcid0000-0002-3949-6897
dc.contributor.orcid0000-0001-6098-1603
dc.date.accessioned2025-11-13T10:51:06Z
dc.date.issued2021-11-05
dc.identifier.doihttps://doi.org/10.1182/blood-2021-148082
dc.identifier.endpage306
dc.identifier.issn0006-4971
dc.identifier.issueSupplement 1
dc.identifier.openalexW3214593761
dc.identifier.startpage306
dc.identifier.urihttps://hdl.handle.net/11421/5450
dc.identifier.urihttps://doi.org/10.1182/blood-2021-148082
dc.identifier.volume138
dc.language.isoen
dc.relation.ispartofBlood
dc.rightsrestrictedAccess
dc.subjectMedicine
dc.subjectRefractory (planetary science)
dc.subjectPembrolizumab
dc.subjectInternal medicine
dc.subjectLymphoma
dc.subjectPhases of clinical research
dc.subjectOncology
dc.subjectSurgery
dc.subjectChemotherapy
dc.subjectImmunotherapy
dc.subjectCancer
dc.subject.sdg3
dc.titleFinal Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications